About: Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT(1) receptor axis vs. ACE2–angiotensin-(1–7)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT(1) receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT(1) receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
Creator	Horiuchi, Masatsugu Iwai, Masaru
source	Medline; PMC
abstract	Recent studies have established a new regulatory axis in the renin–angiotensin system (RAS). In this axis, angiotensin (Ang)-(1–7) is finally produced from Ang I or Ang II by the catalytic activity of angiotensin-converting enzyme 2 (ACE2). Ang-(1–7) shows actions different from those of AT(1) receptor stimulation, such as vasodilatation, natriuresis, anti-proliferation and an increase in the bradykinin–NO (nitric oxide) system. As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT(1) receptor axis. The signaling pathway of the ACE2–Ang-(1–7) axis has not yet been totally and clearly understood. However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1–7). Intracellular signaling through Mas is not clear yet. Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1–7). However, this second axis through ACE2 and Ang-(1–7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders.
has issue date	2009-05-22(xsd:dateTime)
bibo:doi	10.1038/hr.2009.74
bibo:pmid	19461648
has license	no-cc
sha1sum (hex)	f22ac602926d152936dd6af839da45bf8290e038
schema:url	https://doi.org/10.1038/hr.2009.74
resource representing a document's title	Devil and angel in the renin–angiotensin system: ACE–angiotensin II–AT(1) receptor axis vs. ACE2–angiotensin-(1–7)–Mas receptor axis
has PubMed Central identifier	PMC7091931
has PubMed identifier	19461648
schema:publication	Hypertens Res
resource representing a document's body	covid:f22ac602926d152936dd6af839da45bf8290e038#body_text
is schema:about of	named entity 'cardiovascular' named entity 'RAS' named entity 'However' named entity 'Mas' named entity 'fold' named entity 'higher' named entity 'receptor' named entity 'RECEPTOR' named entity 'ANGIOTENSIN' named entity 'SIGNALING PATHWAY' named entity 'POSSIBLY' named entity 'KINASE' named entity 'COUNTER' named entity 'PROTEIN KINASE C ACTIVATION' named entity 'NEEDED' named entity 'REGULATORY' named entity 'ANG II' named entity 'DIFFERENT' named entity 'ESTABLISHED' named entity 'MECHANISM OF ACTION' named entity 'NEW' named entity 'PROLIFERATION' named entity 'STIMULATION' named entity 'BRADYKININ' named entity '400' named entity 'METABOLIC DISORDERS' named entity 'ANGIOTENSIN' named entity 'TARGET' named entity 'VASODILATATION' named entity 'HIGHER' covid:arg/f22ac602926d152936dd6af839da45bf8290e038 named entity 'ACE2' named entity 'HAVE' named entity 'CARDIOVASCULAR' named entity 'THERAPY' named entity 'MITOGEN-ACTIVATED PROTEIN' named entity 'RECENT' named entity 'ANGIOTENSIN II' named entity 'ACE' named entity 'DEVIL' named entity 'MAS RECEPTOR' named entity 'INVESTIGATIONS' named entity 'OXIDE' named entity 'SYSTEM' named entity 'ANGIOTENSIN-CONVERTING ENZYME 2' named entity 'STUDIES' named entity 'REPORT' named entity 'CATALYTIC ACTIVITY' named entity 'MAS ONCOGENE' named entity 'CLEAR' named entity 'IMPORTANT' named entity 'ANG I' named entity 'UNDERSTOOD' named entity 'RAS' named entity 'ANG' named entity 'SECOND' named entity 'RECEPTOR' named entity 'APPROXIMATELY' named entity 'CLARIFY' named entity 'INVOLVED' named entity 'TOTALLY' named entity 'PHOSPHORYLATION' named entity 'ACTIONS' named entity 'NATRIURESIS' named entity 'AXIS' named entity 'INCREASE' named entity 'ACE' named entity 'INTRACELLULAR SIGNALING' named entity 'SUBSTRATE' named entity 'PROTEIN ' named entity 'REGULATORY SYSTEM' named entity 'FOLD' named entity 'RENIN-ANGIOTENSIN SYSTEM' named entity 'INHIBITION' named entity 'AKT' named entity 'ACTS' named entity 'CATALYTIC EFFICIENCY' named entity 'REGULATION' named entity 'ANGEL' named entity 'AXIS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software